These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 15456957)

  • 1. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
    Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
    Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
    Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
    Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
    J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
    Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization.
    Durán-Prado M; Bucharles C; Gonzalez BJ; Vázquez-Martínez R; Martínez-Fuentes AJ; García-Navarro S; Rhodes SJ; Vaudry H; Malagón MM; Castaño JP
    Endocrinology; 2007 Jan; 148(1):411-21. PubMed ID: 17053026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
    Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
    Schaer JC; Waser B; Mengod G; Reubi JC
    Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
    Schmid HA; Schoeffter P
    Neuroendocrinology; 2004; 80 Suppl 1():47-50. PubMed ID: 15477717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC; Piccin D; Bottoni A; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Taylor JE; Culler MD; Cavazzini L; degli Uberti EC
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
    Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
    Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
    Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.
    Zatelli MC; Tagliati F; Piccin D; Taylor JE; Culler MD; Bondanelli M; degli Uberti EC
    Biochem Biophys Res Commun; 2002 Oct; 297(4):828-34. PubMed ID: 12359227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
    Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
    Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.